rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2008-4-4-18-22rpcardio-1131Research ArticleORIGINAL STUDIESОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯLOVASTATIN EFFECT ON VASCULAR REMODELING AND MYOCARDIAL SYSTOLIC AND DIASTOLIC FUNCTION IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASEВЛИЯНИЕ ЛОВАСТАТИНА НА СОСУДИСТОЕ РЕМОДЕЛИРОВАНИЕ И СИСТОЛО-ДИАСТОЛИЧЕСКУЮ ФУНКЦИЮ МИОКАРДА У БОЛЬНЫХ СТАБИЛЬНОЙ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦАКеримкуловаА. С.KerimkulovaA. S.alinakg@gmail.comНорузбаеваА. М.NoruzbaevaA. M.alinakg@gmail.comЛунеговаО. С.LunegovaO. S.alinakg@gmail.comИмановБ. Ж.ImanovB. Z.alinakg@gmail.comПавленкоМ. А.PavlenkoM. A.alinakg@gmail.comМиррахимовА. Э.MirrahimovA. E.alinakg@gmail.comГотфридИ. Ю.GottfriedI. JU.alinakg@gmail.comМиррахимовЭ. М.MirrahimovE. M.alinakg@gmail.comКыргызская государственная медицинская академия, Кыргызстан 720020, Бишкек, ул. Ахунбаева, 92КыргызстанKyrgyz State Medical Academy, Akhunbaeva ul. 92, Bishkek, 720020 Kyrgyz RepublicKyrgyzstanНациональный центр кардиологии и терапии им. акад. Мирсаида МиррахимоваКыргызстанNational Center of Cardiology and Therapy named after academician MIrsaid MirrahimovKyrgyzstanКыргызско-Российский Славянский университет; БишкекКыргызстанKyrghyz-Russian Slavic University; BishkekKyrgyzstan200831012016441822Copyright © Kerimkulova A.S., Noruzbaeva A.M., Lunegova O.S., Imanov B.Z., Pavlenko M.A., Mirrahimov A.E., Gottfried I.J., Mirrahimov E.M., 20162016Керимкулова А.С., Норузбаева А.М., Лунегова О.С., Иманов Б.Ж., Павленко М.А., Миррахимов А.Э., Готфрид И.Ю., Миррахимов Э.М.Kerimkulova A.S., Noruzbaeva A.M., Lunegova O.S., Imanov B.Z., Pavlenko M.A., Mirrahimov A.E., Gottfried I.J., Mirrahimov E.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1131Aim

Aim. To study effect of 12-month therapy with lovastatin on vascular remodeling, systolic and diastolic functions of left ventricle (LV).

Material and methods

Material and methods. 84 patients (54,3±6,5 y.o.) with ischemic heart disease (IHD) and dislipoproteinemia were involved in the study. Patients were randomized into 2 groups. Patients of the 1st group (n=44) received lovastatin (20-60 mg daily) in addition to hypolipidemic diet and standard therapy. Patients of the 2nd group (n=39) were treated with diet and standard therapy only. Lipid spectrum and transaminase blood levels estimation, carotid duplex ultrasonography, echocardiography were performed initially and after 12 months of treatment.

Results

Results. Decrease of carotid intima-media thickness, delay of increasing of LV myocardium mass index, increase of LV ejection fraction was observed in 12 months of treatment in patients of the 1st group. There were not any changes of LV diastolic function in both groups.

The conclusion

The conclusion. In patients with IHD and dislipoproteinemia 12 month lovastatin therapy prevents of vascular remodeling and improves LV systolic function.

Цель

Цель. Изучить влияние 12-месячной терапии ловастатином на сосудистое ремоделирование, систолическую и диастолическую функции левого желудочка (ЛЖ).

Материал и методы

Материал и методы. В исследование были включены 84 пациента с ишемической болезнью сердца (ИБС) и дислипидемией в возрасте 42-65 (54,3±6,5) лет. Больных рандомизировали по группам: в 1-й группе (n=44) дополнительно к гиполипидемической диете и стандартной базисной терапии назначали ловастатин (20-60 мг/сут); во 2-й группе (n=39) применялись только диета и стандартная базисная терапия. Исходно и через 12 мес определяли липидный спектр, трансаминазы; про- водили дуплексное сканирование сонных артерий, эхокардиографию.

Результаты

Результаты. По завершении 12-месячного периода лечения ловастатином в 1-й группе наряду с гиполипидемическим эффектом выявлены снижение толщины комплекса интима-медиа сонных артерий, замедление нарастания индекса массы миокарда ЛЖ, повышение фракции выброса ЛЖ. Изменения показателей диастолической функции ЛЖ отсутствовали в обеих группах.

Заключение

Заключение. У больных ИБС с дислипидемией 12-месячная терапия ловастатином предупреждает сосудистое ремоделирование и улучшает систолическую функцию ЛЖ.

статинытолщина комплекса интима-медиаремоделированиефракция выбросаишемическая болезнь сердцаstatinsintima-media thicknessremodelingejection fractionischemic heart diseaseReferencesSacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-9.Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335(14):1001-9.Liao J.K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.Liao J.K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118.Salonen J.R., Salonen R. Ultrasonographicaly assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991;11(5):1245-9.Salonen J.R., Salonen R. Ultrasonographicaly assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991;11(5):1245-9.Jashnani K.D., Kulkarni R.R., Deshpande J.R. Role of carotid intimamedia thickness in assessment of atherosclerosis: an autopsy study. Indian Heart J 2005;57(4):319-23.Jashnani K.D., Kulkarni R.R., Deshpande J.R. Role of carotid intimamedia thickness in assessment of atherosclerosis: an autopsy study. Indian Heart J 2005;57(4):319-23.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001; 285(19):2486-97.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001; 285(19):2486-97.Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458.Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-458.European Carotid Surgery Trialists` Collaborative Group. MRC – European Carotid Surgery Trial: interim results for symptomatic patients with severe (70 – 99%) or with mild (0 – 29%) carotid stenosis. Lancet 1991; 337(8752):1235-43.European Carotid Surgery Trialists` Collaborative Group. MRC – European Carotid Surgery Trial: interim results for symptomatic patients with severe (70 – 99%) or with mild (0 – 29%) carotid stenosis. Lancet 1991; 337(8752):1235-43.Downs J.R., Clearfield M., Tyroler H.A., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001;87:1074-9.Downs J.R., Clearfield M., Tyroler H.A., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001;87:1074-9.Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA 2004;291:1071-80.Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA 2004;291:1071-80.Grundy S.M., Cleeman J.I., Merz C.N.B., et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32.Grundy S.M., Cleeman J.I., Merz C.N.B., et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32.Lorenz M.W., von Kegler S., Steinmetz H., et al. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006;37:87-92.Lorenz M.W., von Kegler S., Steinmetz H., et al. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006;37:87-92.Ferrier K.E., Muhlmann M.H., Baguet J.P., et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39(6):1020-5.Ferrier K.E., Muhlmann M.H., Baguet J.P., et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39(6):1020-5.Mital S., Liao J.K. Statins and the myocardium. Semin Vasc Med 2004;4:377-84.Mital S., Liao J.K. Statins and the myocardium. Semin Vasc Med 2004;4:377-84.Hasegawa H., Yamamoto R., Takano H., et al. 3-Hydroxy-3- methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003;35(8):953–960.Hasegawa H., Yamamoto R., Takano H., et al. 3-Hydroxy-3- methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003;35(8):953–960.Nishikawa H., Miura S., Zhang B., et al. Statins induce the regression of left ventricular mass in patients with angina. Circ J 2004;68(2):121- 5.Nishikawa H., Miura S., Zhang B., et al. Statins induce the regression of left ventricular mass in patients with angina. Circ J 2004;68(2):121- 5.Sola S., Mir M.Q., Lerakis S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332-7.Sola S., Mir M.Q., Lerakis S., et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332-7.

The authors declare that there are no conflicts of interest present.